FBIO

Fortress Biotech, Inc.

2.71 USD

Last updated Sep 4, 19:51 UTC

Yesterday HIGH

$2.76

Yesterday LOW

$2.7

52w HIGH

$4.53

52w LOW

$2.18

EPS

-0.08

PE

-33.88

Next Earnings

Nov 13, 2026

Overview News Unusual Options Flow Government Trades Fundamentals

Fortress Biotech, Inc. stock is down -2.87% since 30 days ago. The next earnings date is Nov 13, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 20% of the previous 14 September’s closed higher than August. In the last 1 Unusual Options Trades, there were 1 CALL.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

09 Jul 15:49	15 Jan, 2027	2.50	CALL	2000	575

Advanced Data Unlock

Benzinga Newsdesk

Thu Aug 13, 2026

Fortress Biotech Q2 EPS $(0.08) Beats $(0.20) Estimate, Sales $18.718M Beat $18.300M Estimate
Benzinga Insights

Mon Aug 3, 2026

12 Health Care Stocks Moving In Monday's Intraday Session

Gainers Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 108.5% to $6.59 during Monday's regular session. The market value of their outstanding shares is at $2.0 million. SL Science Holding (NASDAQ:SLBT)
Benzinga Newsdesk

Mon Jul 27, 2026

Fortress Biotech’s Urica Therapeutics Says Crystalys Closes Oversubscribed $130M Series B Financing To Support Late-Stage Global Clinical Development And Commercialization Preparation For Dotinurad

Urica Therapeutics, Inc. ("Urica" or the "Company"), a Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") subsidiary, today announced that Crystalys Therapeutics, Inc. ("Crystalys"), in
Benzinga Newsdesk

Thu May 14, 2026

Fortress Biotech Q1 EPS $2.82 Beats $(0.22) Estimate, Sales $16.038M Miss $16.338M Estimate

Fortress Biotech (NASDAQ:FBIO) reported quarterly earnings of $2.82 per share which beat the analyst consensus estimate of $(0.22) by 1381.82 percent. This is a 687.5 percent increase over losses of $(0.48) per share
Benzinga Newsdesk

Tue Apr 21, 2026

Fortress Biotech Subsidiary Journey Medical Expands U.S. Market Access For Emrosi Following Third Group Purchasing Contract

SNOW $337.78 USD

TSLA $353.20 USD

SMCI $39.32 USD

ALAB $312.28 USD

LLY $1,143.03 USD

TWST $124.44 USD

PATH $15.12 USD

AAPL $320.94 USD